The role of c-myc in regulation of translation initiation
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Translation initiation is important for the regulation of both cell growth and cell division. It is uniquely poised to coordinate overall cell proliferation by its effects on both growth and division. A number of translation initiation factors are transcriptional targets of c-myc in a variety of assays. In particular, the mRNA cap-binding protein eIF4E has a myc-binding sequence in its promoter that is myc responsive in reporter assays and contains a high-affinity myc-binding site in chromosome immunoprecipitation experiments. Several differential expression screens have demonstrated altered levels of eIF4E, along with several other translation initiation factors, in response to alterations of c-myc levels. The potential for eIF4E and other translational control elements to mediate myc's transforming functions is particularly important because eIF4E is itself a known oncogenic factor. The ability of translation initiation factors to affect both cell division control and cell growth control coincides with myc's remarkable effects on both cell growth and cell division.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, MYC is a well-established regulator of ribosome biogenesis and protein translation, including cap-dependent translation, and can rewire translational control in tumor cells when it is overexpressed (29–31).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [30]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
An analysis of vertebrate mRNA sequences: intimations of translational control.
Kozak, M. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.4.887 · Cited by 1,635
Translational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Translational control of gene expression
Hannig, E. M. (2001) · BioEssays · doi:10.1002/bies.1108 · Cited by 1,189
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Genomic targets of the human c-Myc protein
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A., & Amati, B. (2003) · Genes & Development · doi:10.1101/gad.1067003 · Cited by 973
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951 · cited 1×
“Those changes include development of resistance to growth inhibition, evasion of apoptosis, immortalization, development of mitogenic independence, acquisition of autologous angiogenic regulation, and development of intrinsic invasive properties (Hanahan and Weinberg, 2000; Hahn and Weinberg, 2002).”
BackgroundDeregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 879
Research works printed but not linked: 2
- Packham G and Cleveland JL . (1994). Mol. Cell. Biol., 14, 5741–5747. · doi:10.1128/mcb.14.9.5741-5747.1994 · Paper page
- Rosenwald IB, Lazaris-Karatzas A, Sonenberg N and Schmidt EV . (1993a). Mol. Cell. Biol., 13, 7358–7363. · doi:10.1128/mcb.13.12.7358-7363.1993 · Paper page
Cited by
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607
“It is noteworthy that the mRNAs encoding several protein inhibitors of apoptosis (XIAP, c-IAP1 and BCl-2) and pro-apoptotic proteins (c-Myc, APAF-1) contain internal ribosomal entry sites (IRES), which serve to sustain translation during apoptosis, when cap-dependent expression is suppressed (reviewed in Proud, 2004).”
BackgroundInfluentialSignaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
“…function as a mechanism sensing elevated RP translation, such as the increase in global translation 372 Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc. caused by overexpression of the proto-oncogene c-Myc (Schmidt, 2004) or the rise of RPL11 level by RPS6 knockdown (Fumagalli et al., 2009).”
BackgroundAggarwal, S., Ichikawa, H., Takada, Y., Sandur, S. K., Shishodia, S., & Aggarwal, B. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017400 · Cited by 532
“The role of c-myc in proliferation of tumor is well established (Schmidt, 2004).”
BackgroundJackman, D. M., & Johnson, B. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67569-1 · Cited by 503
An overview of the basic helix-loop-helix proteins.
Jones, S. (2004) · Genome biology · doi:10.1186/gb-2004-5-6-226 · Cited by 643
“Myc proteins are known to regulate translation initiation [37] and they also function as transcriptional activators when they form heterodimers with Max proteins (also members of group B) [38].”
BackgroundKalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
MYC and metabolism on the path to cancer
Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E., & Dang, C. V. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.003 · Cited by 332
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., & Sikic, B. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1204 · Cited by 311
“(57) and regulation of translation initiation (58).”
EMT in cervical cancer: Its role in tumour progression and response to therapy
Qureshi, R., Arora, H., & Rizvi, M. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.09.021 · Cited by 301
eIF4E is a central node of an RNA regulon that governs cellular proliferation
Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., & Borden, K. L. B. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200607020 · Cited by 293
“Importantly, eIF4E does not promote the expression of negative regulators of itself (i.e., PML). eIF4E also promotes the expression of c-myc, a factor that up-regulates the transcription of eIF4E in some cellular growth conditions (Schmidt, 2004).”
BackgroundPourdehnad, M., Truitt, M. L., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., & Ruggero, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310230110 · Cited by 286
“For example, Myc is known to transcriptionally activate the eIF4E oncogene (39), a finding we validated at the protein level in human DLBCL (Fig.”
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Nucleolar Stress: hallmarks, sensing mechanism and diseases
Yang, K., Yang, J., & Yi, J. (2018) · Cell Stress · doi:10.15698/cst2018.06.139 · Cited by 283
“An increased RPs-MDM2 interaction could follow diverse cellular disturbances, such as global translation inhibition [121], or the breakdown of ribosomal polysomes in the cytoplasm [33, 43, 115].”
BackgroundChng, W.-J., Huang, G. F., Chung, T. H., Ng, S. B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 270
The Organizing Principles of Eukaryotic Ribosome Recruitment
Pelletier, J., & Sonenberg, N. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111042 · Cited by 271
“Its transcription is stimulated by the c-MYC (MYC) proto-oncogene product (11, 12), andMYC translation is eIF4E responsive, establishing an oncogenic self-sustaining feedforward loop (13).”
BackgroundThe Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc
Prensner, J. R., Chen, W., Han, S., Iyer, M. K., Cao, Q., Kothari, V., Evans, J. R., Knudsen, K. E., Paulsen, M. T., Ljungman, M., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.001 · Cited by 256
“Conversely, analysis of 93 genes upregulated by PCAT-1 and dependent on cMyc demonstrated an enrichment of genes involved in protein biosynthesis and transcriptional elongation, welldescribed functions of cMyc (Table W3) [20,21].”
BackgroundAutophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation
Carew, J. S., Medina, E. C., Esquivel II, J. A., Mahalingam, D., Swords, R., Kelly, K., Zhang, H., Huang, P., Mita, A. C., Mita, M. M., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00832.x · Cited by 219
“A hallmark feature of aggressive cancers is a general increase in protein synthesis and protein degradation, both of which are required to increase tumour growth [1].”
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Hölzel, M., Rohrmoser, M., Schlee, M., Grimm, T., Harasim, T., Malamoussi, A., Gruber-Eber, A., Kremmer, E., Hiddemann, W., Bornkamm, G. W., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501141 · Cited by 205
“The fact that the oncogenic transcription factor c-Myc efficiently promotes proliferation might result from its capacity to positively regulate both ribosome biogenesis and cell cycle progression (Schmidt, 1999, 2004).”
BackgroundWhen translation meets transformation: the mTOR story
Averous, J., & Proud, C. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209887 · Cited by 197
“In addition to the reported ability of c-myc to increase the level of expression of other proteins involved in translation (reviewed in Schmidt, 2004), it likely also cooperates with eIF4E in transformation by virtue of its ability to counter the effect of eIF4E on cellular senescence.”
BackgroundMore than just proliferation: Myc function in stem cells
Murphy, M. J., Wilson, A., & Trumpp, A. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.01.008 · Cited by 187
Srivastava, N. S., & Srivastava, R. A. K. (2019) · Phytomedicine · doi:10.1016/j.phymed.2018.09.224 · Cited by 178
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2
Hu, W., Feng, Z., & Levine, A. J. (2012) · Genes & Cancer · doi:10.1177/1947601912454734 · Cited by 175
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Cancer therapeutics: Targeting the dark side of Myc
Ponzielli, R., Katz, S., Barsyte-Lovejoy, D., & Penn, L. Z. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.017 · Cited by 168
Translational Repression by RNA-Binding Protein TIAR
Mazan-Mamczarz, K., Lal, A., Martindale, J. L., Kawai, T., & Gorospe, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2716-2727.2006 · Cited by 158
Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
Cowling, V. H., & Cole, M. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01828-06 · Cited by 148
“A small increase in HSP60 polysome loading was observed in response to MycWT, and this may be a reflection of the increased expression of eukaryotic initiation factors 4E and 4G induced by MycWT (but not Myc DNA binding mutants) (47).”
BackgroundČuljković, B., Topisirović, I., & Borden, K. L. B. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3688 · Cited by 181
Lamb, R., Bonuccelli, G., Ozsvári, B., Peiris-Pagès, M., Fiorillo, M., Smith, D. L., Bevilacqua, G., Mazzanti, C. M., McDonnell, L. A., Naccarato, A. G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5852 · Cited by 145
Lynch, M., Chen, L., Ravitz, M. J., Mehtani, S., Korenblat, K., Pazin, M. J., & Schmidt, E. V. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6436-6453.2005 · Cited by 126
“eIF4E is a candidate myc target gene (86), and hnRNP K is one of the most important transcriptional controls of the c-myc promoter (36, 62, 95, 98).”
BackgroundSelf-citationNawrocki, S. T., Carew, J. S., Maclean, K. H., Courage, J. F., Huang, P., Houghton, J. A., Cleveland, J. L., Giles, F. J., & McConkey, D. J. (2008) · Blood · doi:10.1182/blood-2007-12-130823 · Cited by 121
Boddupally, P. V. L., Hahn, S., Beman, C., De, B., Brooks, T. A., Gokhale, V. M., & Hurley, L. H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300282c · Cited by 117
The Oncogene eIF4E: Using Biochemical Insights to Target Cancer
Carroll, M. P., & Borden, K. L. B. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0142 · Cited by 130
The eIF4E RNA regulon promotes the Akt signaling pathway
Čuljković, B., Tan, K., Orolicki, S., Amri, A., Meloche, S., & Borden, K. L. B. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200707018 · Cited by 112
“Interestingly, both eIF4E and NBS1 are direct transcriptional targets of c-Myc ( Chiang et al., 2003 ; Schmidt, 2004 ).”
Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib
Chen, S., Blank, J. L., Peters, T., Liu, X. J., Rappoli, D. M., Pickard, M. D., Menon, S., Yu, J., Driscoll, D. L., Lingaraj, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4428 · Cited by 111
“Myc, which regulates 15% of the genome (27), controls multiple steps within protein translation, including ribosome biogenesis and translation initiation, glycolysis, mitochondrial homeostasis, polyamine biosynthesis, and iron metabolism (23).”
BackgroundSignal Transduction in Ribosome Biogenesis: A Recipe to Avoid Disaster
Piazzi, M., Bavelloni, A., Gallo, A., Faenza, I., & Blalock, W. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112718 · Cited by 121
“MYC also enhances expression of the translation initiation factors eIF2α, eIF4A-I, eIF4E, and eIF4G, which regulate CAP-dependent translation and may also promote methylation of the mRNA CAP through RNA guaine-7-methytransferase [8,37].”
BackgroundRibosomal proteins as novel players in tumorigenesis
Heras-Rubio, A. D. L., Perucho, L., Paciucci, R., Vilardell, J., & LLeonart, M. E. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9460-6 · Cited by 95
Ichikawa, H., Takada, Y., Murakami, A., & Aggarwal, B. B. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7383 · Cited by 98
“The role of c-Myc in the proliferation of tumor is well established (42).”
BackgroundSIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency
Herranz, D., Maraver, A., Cañamero, M., Goméz-López, G., Inglada‐Pérez, L., Robledo, M., Castelblanco, E., Matías‐Guiu, X., & Serrano, M. (2012) · Oncogene · doi:10.1038/onc.2012.407 · Cited by 91
Murata, T., & Shimotohno, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600563200 · Cited by 81
Ichikawa, H., Nair, M. S., Takada, Y., Sheeja, D. B. A., Kumar, M. A. S., Oommen, O. V., & Aggarwal, B. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0916 · Cited by 88
Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies
Bilanges, B., & Stokoe, D. (2007) · Oncogene · doi:10.1038/sj.onc.1210431 · Cited by 95
“…how other commonly mutated oncogenes and tumor suppressors directly impact on translational regulation, it should be noted that myc increases the transcription of many ribosomal proteins, initiation factors, and rRNA ( Schmidt, 2004), and p53 inhibits rRNA transcription (Zhai and Comai, 2000).”
BackgroundSpecific regulation of mRNA cap methylation by the c-Myc and E2F1 transcription factors
Cole, M. D., & Cowling, V. H. (2009) · Oncogene · doi:10.1038/onc.2008.463 · Cited by 75
“…upregulating mRNA cap methylation, c-Myc has previously been demonstrated to increase expression of translation factors including eIF4E and eIF4G (Schmidt, 2004), to increase expression of ribosomal and nucleolar proteins (Boon et al., 2001; Guo et al., 2000; Kim et al., 2000; Schuhmacher et…”
BackgroundTargeting RNA polymerase I to treat MYC-driven cancer
Poortinga, G., Quinn, L. M., & Hannan, R. D. (2014) · Oncogene · doi:10.1038/onc.2014.13 · Cited by 84
Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age
Pandolfi, P. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207618 · Cited by 82
“…targets’ for cancer therapy (Bader and Vogt, 2004; Clemens, 2004; De Benedetti and Graff, 2004; Fingar and Blenis, 2004; Holland et al., 2004; Mamane et al., 2004; Perrotti and Calabretta, 2004; Rajasekhar and Holland, 2004; Rosenwald, 2004; Schmidt, 2004; Stoneley and Willis, 2004; White, 2004).”
BackgroundThe eukaryotic translation initiation factor eIF 4E in the nucleus: taking the road less traveled
Osborne, M. J., & Borden, K. L. B. (2014) · Immunological Reviews · doi:10.1111/imr.12240 · Cited by 74
“Traditionally, eIF4E transcription is considered to be controlled only by c-myc (42); however, serum stimulation still leads to elevated eIF4E levels in c-myc null cells (43).”
BackgroundEukaryotic initiation factor 4E
Goodfellow, I., & Roberts, L. O. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.10.023 · Cited by 91
“Serum, growth factors or immunological activation in T cells have all been shown to lead to increased transcription of the eIF4E gene (Schmidt, 2004).”
Zheng, Z. S., Jia, J., Zhang, X., Zara, J. N., Yin, W., Chiang, M., Liu, Y., Wang, J., Pang, S., Ting, K., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.049 · Cited by 72
The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications
Xu, Y., & Ruggero, D. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033420 · Cited by 67
Yeomans, A., Thirdborough, S. M., Valle‐Argos, B., Linley, A. J., Krysov, S. V., Sánchéz‐Hidalgo, M., Leonard, E., Ishfaq, M., Wagner, S. D., Willis, A. E., et al. (2015) · Blood · doi:10.1182/blood-2015-07-660969 · Cited by 74
Agnelli, L., Fabris, S., Bicciato, S., Basso, D., Baldini, L., Morabito, F., Verdelli, D., Todoerti, K., Lambertenghi‐Deliliers, G., Lombardi, L., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06467.x · Cited by 66
“Various studies have demonstrated an increase in the expression levels of eif4 family factors (which was also found to be upregulated in H-MM), as well as of several other translation initiation factors, in response to deregulated c-myc expression (Schmidt, 2004).”
BackgroundEnolase-1 is a therapeutic target in endometrial carcinoma
Zhao, M., Fang, W., Wang, Y., Guo, S., Shu, L., Wang, L., Chen, Y., Fu, Q., Liu, Y., Hua, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3639 · Cited by 64
Čuljković, B., & Borden, K. L. B. (2009) · Journal of Oncology · doi:10.1155/2009/981679 · Cited by 69
“For instance, eIF4E levels are elevated, at least in part, in breast cancer and head and neck squamous cell carcinomas due to amplification of the eIF4E gene [13, 104, 105].”
BackgroundFernández-Sánchez, M. E., Gonatopoulos-Pournatzis, T., Preston, G., Lawlor, M. A., & Cowling, V. H. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00973-09 · Cited by 64
“mechanisms including increased mRNA production, mRNA cap methylation, increased rRNA and tRNA production, and increased translation factor and ribosomal protein production (6, 18, 32).”
BackgroundPopis, M. C., Blanco, S., & Frye, M. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000252 · Cited by 58
“Myc plays an important role in regulating protein translation through transcriptional regulation of RNA and protein components of ribosomes and translation initiation factors [94,95].”
BackgroundExploring Dysregulated Signaling Pathways in Cancer
Nisar, S., Hashem, S., Macha, M. A., Yadav, S. K., Muralitharan, S., Therachiyil, L., Sageena, G., Al‐Naemi, H. A., Haris, M., & Bhat, A. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115095937 · Cited by 60
Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway
Schmidt, E. V., Ravitz, M. J., Chen, L., & Lynch, M. C. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8215 · Cited by 58
Self-citationThe functional sites of miRNAs and lncRNAs in gastric carcinogenesis
Wan, X., Ding, X., Chen, S., Song, H., Jiang, H., Fang, Y., Li, P., & Guo, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3136-5 · Cited by 58
“cMyc and eIF4E can promote each other [52].”
BackgroundRavitz, M. J., Chen, L., Lynch, M., & Schmidt, E. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4351 · Cited by 54
“Known targets of growth regulation by myc include RNA polymerases I and III, ribosomal proteins, and eIF4E (8).”
BackgroundSelf-citationDyshlovoy, S. A., Venz, S., Shubina, L. K., Fedorov, S. N., Walther, R., Jacobsen, C., Stonik, V. A., Bokemeyer, C., Balabanov, S., & Honecker, F. U. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.11.009 · Cited by 58
“[38] Schmidt EV.”
BackgroundGenome-wide analysis of YY2 versus YY1 target genes
Chen, L., Shioda, T., Coser, K. R., Lynch, M. C., Yang, C., & Schmidt, E. V. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq112 · Cited by 49
Self-citationDirect regulation of the minichromosome maintenance complex by MYCN in neuroblastoma
Koppen, A., Ait‐Aissa, R., Köster, J., Sluis, P. V., Øra, I., Caron, H. N., Volckmann, R., Versteeg, R., & Valentijn, L. J. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.024 · Cited by 54
Yin, J., Dong, Z., Liu, Z., & Zhang, J. (2010) · Bioscience Reports · doi:10.1042/bsr20100077 · Cited by 56
eIF4E as a Control Target for Viruses
Montero, H., García‐Román, R., & Mora, S. I. (2015) · Viruses · doi:10.3390/v7020739 · Cited by 60
“eIF4E is a transcriptional target of c-Myc [38]; interestingly, overexpression of eIF4E has been observed to cause malignant transformation of human epithelial cells and fibroblasts and promote tumor formation in transgenic mice [39,40].”
BackgroundDey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 57
McClusky, D. R., Chu, Q. D., Yu, H., Benedetti, A. D., Johnson, L. W., Meschonat, C., Turnage, R. H., McDonald, J. C., Abreo, F. W., & Li, B. D. �. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000184224.55949.90 · Cited by 58
Hoorn, E. J., Hoffert, J. D., & Knepper, M. A. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005030322 · Cited by 49
“Although c-myc is best known as a tumor promotor oncogene, it also has physiologic functions in all cells that seem to be related to the state of differentiation and proliferation through general regulation of transcription and translation (27).”
BackgroundTranslation initiation: a critical signalling node in cancer
Robert, F., & Pelletier, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903241625 · Cited by 48
“An increase in c-Myc activity will transcriptionally upregulate many components of the translation apparatus [55,56], including eIF4E, eIF4G and eIF4A [57,58].”
BackgroundBitra, K., Tan, A., Dowling, A. P. G., & Palli, S. R. (2009) · Gene · doi:10.1016/j.gene.2009.08.003 · Cited by 48
“Myc proteins regulate translation initiation (Schmidt, 2004) and also function as transcriptional activators when they form heterodimers with Max proteins (Schmidt, Bitra et al. Page 5 Gene.”
BackgroundLi, Z., Dong, L., Dean, E. A., & Yang, L. V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020236 · Cited by 53
The Eukaryotic Translation Initiation Factor 4E (eIF4E) as a Therapeutic Target for Cancer
Karaki, S., Andrieu, C., Ziouziou, H., & Rocchi, P. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.09.001 · Cited by 52
“Thus, there are proteins involved in proliferation (cyclin D1, c-Myc, CDK2), apoptosis (survivin, Bcl-2, Mcl-1), angiogenesis (VEGF, FGF2), and metastasis (MMP9, heparanase) (Mamane et al., 2004; Schmidt, 2004; Zimmer et al., 2000) .”
BackgroundInfluentialCap-independent mRNA translation is upregulated in long-lived endocrine mutant mice
Ozkurede, U., Kala, R., Johnson, C., Shen, Z., Miller, R. A., & Garcia, G. G. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0021 · Cited by 47
Translational control: A target for cancer therapy
Thumma, S. C., & Kratzke, R. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.08.022 · Cited by 53
“[15] E.”
Backgroundc-Myc, Genomic Instability and Disease
Kuttler, F., & Mai, S. (2006) · KARGER eBooks · doi:10.1159/000092507 · Cited by 55
Jankiewicz, M., Groner, B., & Desrivières, S. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0071 · Cited by 41
Posternak, V., Ung, M. H., Cheng, C., & Cole, M. D. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0247 · Cited by 39
Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
Wang, L., Arras, J., Katsha, A. M., Hamdan, S. A., Belkhiri, A., Ecsedy, J., & El-Rifai, W. M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12066 · Cited by 40
“Overexpression and activation of c-MYC, by means of increased transcription, translation, or protein stability, is associated with aggressive tumors and poor patient prognosis (Horiuchi et al., 2014; Schmidt, 2004).”
BackgroundDickkopf‐3 expression is a marker for neuroblastic tumor maturation and is down‐regulated by MYCN
Koppen, A., Ait‐Aissa, R., Köster, J., Øra, I., Bras, J., Sluis, P. V., Caron, H. N., Versteeg, R., & Valentijn, L. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.23180 · Cited by 38
Switching on p53: an essential role for protein phosphorylation?
Loughery, J., & Meek, D. W. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.1 · Cited by 49
“Importantly, Myc can stimulate ribosomal protein translation [87] and may therefore contribute to p53 induction by this route.”
The role of X-linked genes in breast cancer
Thakur, A. B., Xu, H., Wang, Y., Bollig-Fischer, A. B., Biliran, H., & Liao, J. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-4516-0 · Cited by 36
eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production
Mars, J.-C., Čuljković, B., & Borden, K. L. B. (2024) · Nucleus · doi:10.1080/19491034.2024.2360196 · Cited by 40
“Myc, an eIF4E target [72,139,140], increased capping for specific groups of mRNAs by increasing phosphorylation of RNA polymerase II, which promotes the recruitment of capping machinery to specific genes [130,137,141], and upregulates the expression of S-adenosyl homocysteine hydrolase (SAHH),…”
BackgroundDarcy, K. M., Brady, W. E., Blancato, J. K., Dickson, R. B., Hoskins, W. J., McGuire, W. P., & Birrer, M. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.012 · Cited by 35
MYC: there is more to it than cancer
Fluck, M. F. Z., Soucek, L., & Whitfield, J. R. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1342872 · Cited by 39
“5 ′ end of mRNAs (Schmidt, 2004).”
Neurotrophin‐3 targets the translational initiation machinery in oligodendrocytes
Coelho, R. P., Yuelling, L. M., Fuss, B., & Sato‐Bigbee, C. (2009) · Glia · doi:10.1002/glia.20888 · Cited by 38
Webb, L., Miranda, J. N., Amici, S. A., Sengupta, S., Nagy, G., & Guerau‐de‐Arellano, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00524 · Cited by 33
Howard, C. M., Estrada, M. D., Terrero, D., Tiwari, A. K., & Raman, D. (2020) · Cancers · doi:10.3390/cancers12082169 · Cited by 35
“There is a long-standing interest in the role of c-MYC and regulation of translational initiation [53].”
BackgroundHolm, N. T., Byrnes, K., Johnson, L., Abreo, F. W., Sehon, K., Alley, J., Meschonat, C., Chu, Q. D., & Li, B. D. �. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0086-9 · Cited by 43
The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
Yan, S., Frank, D. O., Son, J., Hannan, K. M., Hannan, R. D., Chan, K. T., Pearson, R. B., & Sanij, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010210 · Cited by 35
Chen, J., Sathiaseelan, V., Moore, A., Tan, S., Chilamakuri, C. S. R., Franklin, V. N. R., Shahsavari, A., Jakwerth, C. A., Hake, S. B., Warren, A. J., et al. (2021) · Blood · doi:10.1182/blood.2020009960 · Cited by 31
Gillen, S. L., Waldron, J. A., & Bushell, M. (2021) · Oncogene · doi:10.1038/s41388-021-02022-x · Cited by 33
Regulation by c-Myc of ncRNA expression
Kenneth, N. S., & White, R. J. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.11.012 · Cited by 27
He, Y., Jin, Y., Zhang, Y., Meng, H., Zhao, B., Jiang, Y., Zhu, J.-W., Liang, G.-Y., Kong, D., & Jin, X. (2014) · Translational research · doi:10.1016/j.trsl.2014.09.005 · Cited by 27
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
Bhin, J., Yemelyanenko, J., Chao, X., Klarenbeek, S., Opdam, M., Malka, Y., Hoekman, L., Kruger, D. T., Bleijerveld, O. B., Brambillasca, C. S., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20211743 · Cited by 34
“MYC can also act as a master regulator of translation by directly regulating the transcription of the genes involved in translation initiation and elongation, transfer RNA (tRNA) synthetases, and ribosomal proteins (van Riggelen et al., 2010; Schmidt, 2004).”
Campbell, L., Jasani, B., Griffiths, D. F., & Gumbleton, M. (2015) · Europe PMC (PubMed Central) · Cited by 26
Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
Tsoi, H., You, C., Leung, M., Man, E. P. S., & Khoo, U. (2022) · Cancers · doi:10.3390/cancers14051251 · Cited by 25
Metadata
- Authors
- Schmidt, E. V.
- Affiliations
- Harvard University (US)
- Corresponding author
- Schmidt, Emmett V
- ORCID
- Schmidt, Emmett V
- Venue
- Oncogene
- Published
- 2004-04-19
- Volume
- 23
- Issue
- 18
- Pages
- 3217-3221
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1995431293
- Cited by
- 166
- References
- 63
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 12 · 2014: 7 · 2013: 11 · 2012: 8
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA063117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- c-Myc, translation initiation, eIF4E, translation initiation factors, mRNA cap-binding protein, transcriptional regulation, cell proliferation, cell growth regulation, cell division regulation, oncogenic transformation, translational regulation
- MeSH terms
- Animals, Carrier Proteins, Cell Division, Cell Transformation, Neoplastic, Humans, Phosphoproteins, Protein Biosynthesis, Proto-Oncogene Proteins c-myc, Cell Cycle Proteins, Eukaryotic Initiation Factor-4E, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.